Adding ranolazine to glimepiride treatment for patients with type 2 diabetes significantly lowered HbA1c over 24 weeks according to a study published in Diabetes, Obesity, and Metabolism.
Ranolazine is an antianginal agent indicated for chronic angina that may be used with beta-blockers, nitrates, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers, anti-platelet and lipid-lowering therapies. It has been associated with reduced HbA1c in prior angina clinical trials.
Jeremy Pettus, MD, from the University of California, San Diego, CA, and colleagues conducted two Phase 3 trials to assess the efficacy of ranolazine for glycemic control in patients with type 2 diabetes on metformin or glimepiride background therapy. The randomized, double-blind trials enrolled a total of 873 patients with type 2 diabetes to ranolazine 1000mg twice daily vs. placebo added to a glimepiride or metformin background therapy. The primary endpoint was change from baseline in HbA1c at Week 24.
Adding ranolazine to glimepiride background therapy led to a 0.51% (least squares mean [LSM] 95% CI: 0.71, 0.32) decrease from baseline in HbA1c at Week 24 vs. placebo. The proportion of patients achieving an HbA1c <7% also doubled (27.1% vs.14.1%; P=0.001). Adding ranolazine to metformin background therapy did not lead a significant difference in the Week 24 HbA1c change from baseline (LSM difference -0.11%, 95% CI: -0.31, 0.1).
A clear reduction in HbA1c over 24 weeks was seen in type 2 diabetes patients after they added ranolazine to glimepiride. However, researchers concluded it remains unclear “whether an effective regimen of ranolazine added to metformin for glycemic control can be identified.”
For more information visit onlinelibrary.wiley.com.